Research on Tax Planning of R&D Expenses in Pharmaceutical Manufacturing Industry

Abstract

Tax planning serves as a critical component for enterprises to enhance core competitiveness. Strategic planning can effectively reduce tax costs and support the achievement of corporate strategic objectives. As a key industry vital to national economy and people's livelihood, the pharmaceutical manufacturing sector accounts for a significant proportion of operational costs in terms of tax burdens. The government has introduced multiple preferential policies, including the R&D expense super deduction and a 15% reduced tax rate, which can significantly lower corporate tax liabilities when properly utilized. This study focuses on A Pharmaceutical Co., Ltd., examining its tax planning strategies aligned with its strategic goals while ensuring legal compliance, aiming to achieve both tax reduction and post-tax profit maximization. The paper first outlines the research background, significance, and current domestic and international studies, defining key concepts such as pharmaceutical manufacturing, tax planning, R&D expense super deduction, and outsourced R&D, while systematically reviewing relevant tax incentives. It then analyzes the necessity and feasibility of tax planning in the pharmaceutical industry based on its characteristics, development status, and tax-related challenges. Finally, by evaluating the company's operational and tax burden data, the study identifies potential planning opportunities, designs corresponding strategies, compares tax burden and net profit changes before and after planning, selects the optimal solution, summarizes research conclusions, and provides recommendations for tax planning in the pharmaceutical manufacturing sector.